AU Patent

AU2013224947B2 — Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative

Assigned to AIC246 AG and Co KG · Expires 2017-06-29 · 9y expired

What this patent protects

The invention relates to pharmaceutical preparations, in particular for intravenous administration, which contain {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl} acetic acid in combination with at least one auxil…

USPTO Abstract

The invention relates to pharmaceutical preparations, in particular for intravenous administration, which contain {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl} acetic acid in combination with at least one auxiliary agent selected from the cyclodextrins, lysine, and arginine, to methods for the production thereof, and to the use thereof to treat and/or prevent diseases, in particular the use thereof as antiviral agents preferably against cytomegaloviruses.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013224947B2
Jurisdiction
AU
Classification
—
Expires
2017-06-29
Drug substance claim
No
Drug product claim
No
Assignee
AIC246 AG and Co KG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.